179 related articles for article (PubMed ID: 34021119)
1. Real-world renal function among patients with multiple myeloma in the United States.
Mikhael J; Singh E; Rice MS
Blood Cancer J; 2021 May; 11(5):99. PubMed ID: 34021119
[No Abstract] [Full Text] [Related]
2. Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma.
Zanwar S; Ho M; Kapoor P; Dispenzieri A; Lacy MQ; Gertz MA; Buadi FK; Hayman SR; Dingli D; Kourelis T; Fonder A; Hobbs M; Hwa Y; Gonsalves W; Warsame R; Muchtar E; Leung N; Kyle RA; Rajkumar SV; Kumar S
Leukemia; 2022 Mar; 36(3):873-876. PubMed ID: 34635783
[No Abstract] [Full Text] [Related]
3. Epidemiology and Risks of Infections in Patients With Multiple Myeloma Managed With New Generation Therapies.
Lim C; Sinha P; Harrison SJ; Quach H; Slavin MA; Teh BW
Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):444-450.e3. PubMed ID: 33722538
[TBL] [Abstract][Full Text] [Related]
4. [Not Available].
Hitz F
Praxis (Bern 1994); 2016; 105(21):1255-1260. PubMed ID: 28573955
[No Abstract] [Full Text] [Related]
5. Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma.
Wanchoo R; Abudayyeh A; Doshi M; Edeani A; Glezerman IG; Monga D; Rosner M; Jhaveri KD
Clin J Am Soc Nephrol; 2017 Jan; 12(1):176-189. PubMed ID: 27654928
[TBL] [Abstract][Full Text] [Related]
6. Renal impairment and use of nephrotoxic agents in patients with multiple myeloma in the clinical practice setting in the United States.
Qian Y; Bhowmik D; Bond C; Wang S; Colman S; Hernandez RK; Cheng P; Intorcia M
Cancer Med; 2017 Jul; 6(7):1523-1530. PubMed ID: 28612485
[TBL] [Abstract][Full Text] [Related]
7. Update on proteasome inhibitors in multiple myeloma.
Richardson PG
Clin Adv Hematol Oncol; 2014 Mar; 12(3):179-81. PubMed ID: 24927266
[No Abstract] [Full Text] [Related]
8. Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.
Hobeika L; Self SE; Velez JC
BMC Nephrol; 2014 Sep; 15():156. PubMed ID: 25267524
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in proteasome inhibitor-based cancer therapies.
Dou QP
Curr Cancer Drug Targets; 2014; 14(6):505. PubMed ID: 25092106
[No Abstract] [Full Text] [Related]
10. Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor-refractory multiple myeloma.
Driessen C; Müller R; Novak U; Cantoni N; Betticher D; Mach N; Rüfer A; Mey U; Samaras P; Ribi K; Besse L; Besse A; Berset C; Rondeau S; Hawle H; Hitz F; Pabst T; Zander T
Blood; 2018 Nov; 132(19):2097-2100. PubMed ID: 30237154
[No Abstract] [Full Text] [Related]
11. Immunomodulatory Agents and Proteasome Inhibitors in the Treatment of Multiple Myeloma.
Noonan K; Colson K
Semin Oncol Nurs; 2017 Aug; 33(3):279-291. PubMed ID: 28666621
[TBL] [Abstract][Full Text] [Related]
12. Daratumumab combination prolongs myeloma survival.
Das M
Lancet Oncol; 2016 Oct; 17(10):e422. PubMed ID: 27601427
[No Abstract] [Full Text] [Related]
13. Common Adverse Effects of Novel Therapies for Multiple Myeloma (MM) and Their Management Strategies.
McCullough KB; Hobbs MA; Abeykoon JP; Kapoor P
Curr Hematol Malig Rep; 2018 Apr; 13(2):114-124. PubMed ID: 29450683
[TBL] [Abstract][Full Text] [Related]
14. Managing multiple myeloma.
Lee AS; Tsang RY; Sandhu I
CMAJ; 2021 Aug; 193(34):E1349. PubMed ID: 34462295
[No Abstract] [Full Text] [Related]
15. Emerging therapies for multiple myeloma: Application in older adults.
Wildes TM
J Geriatr Oncol; 2017 Nov; 8(6):413-416. PubMed ID: 28756084
[TBL] [Abstract][Full Text] [Related]
16. A practical review on carfilzomib in multiple myeloma.
Muchtar E; Gertz MA; Magen H
Eur J Haematol; 2016 Jun; 96(6):564-77. PubMed ID: 26893241
[TBL] [Abstract][Full Text] [Related]
17. Navigating the treatment landscape in multiple myeloma: which combinations to use and when?
Goldschmidt H; Ashcroft J; Szabo Z; Garderet L
Ann Hematol; 2019 Jan; 98(1):1-18. PubMed ID: 30470875
[TBL] [Abstract][Full Text] [Related]
18. Ixazomib in the management of relapsed multiple myeloma.
Touzeau C; Moreau P
Future Oncol; 2018 Aug; 14(20):2013-2020. PubMed ID: 29469592
[TBL] [Abstract][Full Text] [Related]
19. Proteasome inhibitor-associated thrombotic microangiopathy: A review of cases reported to the FDA adverse event reporting system and published in the literature.
Nguyen MN; Nayernama A; Jones SC; Kanapuru B; Gormley N; Waldron PE
Am J Hematol; 2020 Sep; 95(9):E218-E222. PubMed ID: 32291777
[No Abstract] [Full Text] [Related]
20. Three new drugs for multiple myeloma.
Med Lett Drugs Ther; 2016 May; 58(1495):e70-1. PubMed ID: 27192621
[No Abstract] [Full Text] [Related]
[Next] [New Search]
